Immune checkpoint inhibitors (ICIs) are remarkably effective in some patients with cancer, whereas other patients do not respond or develop resistance over time. Strategies for reinvigorating ...

Editor's note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. So, I think it has a huge impact. It has ...

VIENNA — The highly selective oral Janus kinase (JAK) inhibitor SHR0302 (ivarmacitinib) enables more patients with active rheumatoid arthritis to meet American College of Rheumatology (ACR) response ...

An unprecedented study reveals strategy to decrease the burden of alopecia areata, atopic dermatitis, psoriasis and other autoimmune conditions. A new study published in eLIFE by researchers from the ...

Since the first US Food and Drug Administration approval of a Janus kinase (JAK) inhibitor in 2011, the number of these medications available — and their treatment indications — have continued to grow ...

Onctura initiates phase I/II trial of roginolisib in patients with myelofibrosis who are no longer responding to JAK inhibition: Geneva, Switzerland Friday, December 5, 2025, 15: ...

The Phase II OCULE-01 study in uveal melanoma started in March 2025, the PULMO-01 study in non-small cell lung cancer (NSCLC) started in May 2025 and the HEMA-MED Phase I/II study in myelofibrosis ...

Eli Lilly and Incyte’s oral JAK inhibitor has shown benefit in hair regrowth in paediatric patients with severe alopecia areata. In the Phase III BRAVE-AA-PEDS trial (NCT05723198) 54.1% and 31% of ...

A first-in-class topical pan-Janus kinase (JAK) inhibitor significantly improved symptoms of moderate to severe chronic hand eczema in two randomized phase III trials. At week 16, more patients ...

Real-world data suggested similar effectiveness with tofacitinib or ustekinumab for ulcerative colitis patients with prior biologic failures. However, among those exposed to three or more advanced ...